Articles liés à Signaling Pathways in Breast Cancer: Molecular Mechanisms,...

Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance - Couverture souple

 
9780443490743: Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance

Synopsis

Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance provides an in-depth exploration of the complex molecular mechanisms that drive breast cancer progression. The book focuses on critical signaling pathways, including PI3K/Akt/mTOR, MAPK/ERK, JAK/STAT, Wnt/β-catenin, and Notch, elucidating their roles in tumor development, survival, and therapeutic resistance. The content offers a comprehensive overview of these pathways, detailing their dysregulation in breast cancer and implications for targeted therapeutic strategies. It discusses FDA-approved treatments, emerging therapies, and the mechanisms behind drug resistance, integrating recent research findings to highlight novel molecular targets and biomarker discovery. This book serves as a valuable resource for researchers, clinicians, and students, bridging the gap between basic molecular biology and clinical applications. By providing structured insights into complex signaling networks and therapeutic interventions, it equips readers with essential knowledge for developing innovative approaches to breast cancer management and improving patient outcomes.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

À propos des auteurs

Dr. Sumel Ashique is an Assistant Professor in the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. His academic and research activities focus on drug delivery systems, nanotechnology, and targeted therapeutic strategies. He has several years of teaching experience and has contributed extensively to the scientific literature through publications in national and international peer-reviewed journals. His work centers on the development and application of innovative approaches to improve therapeutic outcomes and advance pharmaceutical sciences.

Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.



Dr. Farzad Taghizadeh-Hesary is an Assistant Professor of Radiation Oncology at Iran University of Medical Sciences, specializing in oncology, radiobiology, and cancer metabolism. He earned his M.D. in 2015 from IUMS and completed a Radiation Oncology residency at Shahid Beheshti University of Medical Sciences, ranking among the top graduates nationally. His thesis examined late toxicities after IMRT for nasopharyngeal carcinoma, reflecting a commitment to precision radiotherapy.

His expertise spans clinical and academic oncology, with a focus on tumor microenvironment and mitochondrial metabolism in cancer. He has published more than 80 peer-reviewed articles and serves on editorial boards including BMC Cancer and PLoS ONE. Awards include the Razi Medical Science Research Prize and the Outstanding Reviewer Award from JCO Clinical Cancer Informatics; Publons Academy ranked him the top global Radiation Oncology reviewer in 2021.

His research centers on personalized radiotherapy, cancer immunotherapy, and metabolic interventions targeting mitochondrial dysfunction, advancing translational oncology



Dr. Vliora Maria is a Molecular Biologist with extensive background in molecular biology and integrative physiology. She has previously studied mutations of immunoglobulins in Chronic Lymphocytic Leukemia patients, and ALK mutations and downstream signaling in Neuroblastoma. Dr. Vliora has a PhD in Biomedical Research from University of Thessaly, Greece and University of Brescia, Italy. She has worked on the development of biocompatible/biodegradable bioscaffolds for targeting adipose tissue as well as on potential nanomedical treatments for brain tumors as well as blood malignancies. Her research work is now focusing on environmental influences that can affect human health and on the use of novel biodegradable bio-scaffolds for allografting adipose stem cells in humans. She collaborated with reputable organizations (WHO, ILO) on projects aiming to enhance human health and wellbeing. She now works as a Project Manager on EU funded projects.

À propos de la quatrième de couverture

Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance provides an in-depth exploration of the complex molecular mechanisms that drive breast cancer progression. The book focuses on critical signaling pathways, including PI3K/Akt/mTOR, MAPK/ERK, JAK/STAT, Wnt/β-catenin, and Notch, elucidating their roles in tumor development, survival, and therapeutic resistance. The content offers a comprehensive overview of these pathways, detailing their dysregulation in breast cancer and the implications for targeted therapeutic strategies. It discusses FDA-approved treatments, emerging therapies, and the mechanisms behind drug resistance, integrating recent research findings to highlight novel molecular targets and biomarker discovery. This book serves as a valuable resource for researchers, clinicians, and students, bridging the gap between basic molecular biology and clinical applications. By providing structured insights into complex signaling networks and therapeutic interventions, it equips the audience with essential knowledge for developing innovative approaches to breast cancer management and improving patient outcomes.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Vos droits au titre de la garantie légale : Chaque consommateur de l'UE bénéficie d'au moins deux ans de protection au titre de la garantie légale pour tout bien de consommation vendu dans l'UE. Voir plus